F. Malard, P. Chevallier, and T. Guillaume, Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution???s Three Decade Experience, Biology of Blood and Marrow Transplantation, vol.20, issue.8, pp.1217-1223, 2014.
DOI : 10.1016/j.bbmt.2014.04.021

T. Gooley, J. Chien, and S. Pergam, Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation, New England Journal of Medicine, vol.363, issue.22, pp.2091-2101, 2010.
DOI : 10.1056/NEJMoa1004383

S. Arai, M. Arora, and T. Wang, Increasing Incidence of Chronic Graft-versus-Host Disease in??Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, Biology of Blood and Marrow Transplantation, vol.21, issue.2, pp.266-274, 2015.
DOI : 10.1016/j.bbmt.2014.10.021

F. Saraceni, N. Shem-tov, A. Olivieri, and A. Nagler, Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective, Bone Marrow Transplantation, vol.112, issue.7, pp.886-891, 2015.
DOI : 10.1038/bmt.2014.330

R. Reshef, A. Huffman, and A. Gao, High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning, Journal of Clinical Oncology, vol.33, issue.21, pp.2392-2398, 2015.
DOI : 10.1200/JCO.2014.60.1203
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500833

A. Chaidos, S. Patterson, and R. Szydlo, Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation, Blood, vol.119, issue.21, pp.5030-5036, 2012.
DOI : 10.1182/blood-2011-11-389304

S. Berzins and D. Ritchie, Natural killer T cells: drivers or passengers in preventing human disease?, Nature Reviews Immunology, vol.63, issue.9, pp.640-646, 2014.
DOI : 10.1038/nri2116

R. Mcewen-smith, M. Salio, and V. Cerundolo, The Regulatory Role of Invariant NKT Cells in Tumor Immunity, Cancer Immunology Research, vol.3, issue.5, pp.425-435, 2015.
DOI : 10.1158/2326-6066.CIR-15-0062

K. Rezvani, S. Mielke, and M. Ahmadzadeh, High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT, Blood, vol.108, issue.4, pp.1291-1297, 2006.
DOI : 10.1182/blood-2006-02-003996

E. Waller, B. Logan, and W. Harris, Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Na??ve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201, Journal of Clinical Oncology, vol.32, issue.22, pp.2365-2372, 2014.
DOI : 10.1200/JCO.2013.54.4577

S. Holtan, T. Defor, and A. Lazaryan, Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, vol.125, issue.8, pp.1333-1338, 2015.
DOI : 10.1182/blood-2014-10-609032

M. Mohty, W. Jacot, and C. Faucher, Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen, Leukemia, vol.17, issue.11, pp.2168-2177, 2003.
DOI : 10.1038/sj.leu.2403105

D. Sutherland, L. Anderson, M. Keeney, R. Nayar, and I. Chin-yee, The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry, Journal of Hematotherapy, vol.5, issue.3, pp.213-226, 1996.
DOI : 10.1089/scd.1.1996.5.213

A. Filipovich, D. Weisdorf, and S. Pavletic, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report, Biology of Blood and Marrow Transplantation, vol.11, issue.12, pp.945-956, 2005.
DOI : 10.1016/j.bbmt.2005.09.004

Y. Kanda, Investigation of the freely available easy-to-use software ???EZR??? for medical statistics, Bone Marrow Transplantation, vol.48, issue.3, pp.452-458, 2013.
DOI : 10.1200/JCO.2007.12.9866

P. Armand, H. Kim, and B. Logan, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, vol.123, issue.23, pp.3664-3671, 2014.
DOI : 10.1182/blood-2014-01-552984

P. Brennan, M. Brigl, and M. Brenner, Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions, Nature Reviews Immunology, vol.181, issue.2, pp.101-117, 2013.
DOI : 10.1038/nri3369

D. Schneidawind, A. Pierini, and M. Alvarez, CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells, Blood, vol.124, issue.22, pp.3320-3328, 2014.
DOI : 10.1182/blood-2014-05-576017

Y. Ilan, M. Ohana, and O. Pappo, Alleviation of Acute and Chronic Graft-Versus-Host Disease in a Murine Model Is Associated with Glucocerebroside-Enhanced Natural Killer T Lymphocyte Plasticity, Transplantation, vol.83, issue.4, pp.458-467, 2007.
DOI : 10.1097/01.tp.0000252783.66886.f3

M. Rubio, L. Moreira-teixeira, and E. Bachy, Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival, Blood, vol.120, issue.10, pp.2144-2154, 2012.
DOI : 10.1182/blood-2012-01-404673

F. Lan, D. Zeng, M. Higuchi, J. Higgins, and S. Strober, Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells, Biology of Blood and Marrow Transplantation, vol.9, issue.6, pp.355-363, 2003.
DOI : 10.1016/S1083-8791(03)00108-3

R. Lowsky, T. Takahashi, and Y. Liu, Protective Conditioning for Acute Graft-versus-Host Disease, New England Journal of Medicine, vol.353, issue.13, pp.1321-1331, 2005.
DOI : 10.1056/NEJMoa050642

J. Scandling, S. Busque, and S. Dejbakhsh-jones, Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants, American Journal of Transplantation, vol.119, issue.4 Suppl 2, pp.1133-1145, 2012.
DOI : 10.1111/j.1600-6143.2012.03992.x

J. Storek, M. Mohty, and J. Boelens, Rabbit Anti???T Cell Globulin in Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.21, issue.6, pp.959-970, 2015.
DOI : 10.1016/j.bbmt.2014.11.676
URL : http://dx.doi.org/10.1016/j.bbmt.2014.11.676

M. Ruzek, K. Neff, and M. Luong, In Vivo Characterization of Rabbit Anti-Mouse Thymocyte Globulin: A Surrogate for Rabbit Anti-Human Thymocyte Globulin, Transplantation, vol.88, issue.2, pp.170-179, 2009.
DOI : 10.1097/TP.0b013e3181abc061

E. Xystrakis, I. Bernard, A. Dejean, T. Alsaati, P. Druet et al., Alloreactive CD4 T???lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset, European Journal of Immunology, vol.34, issue.2, pp.408-417, 2004.
DOI : 10.1002/eji.200324528

M. Bosch, M. Dhadda, and M. Hoegh-petersen, Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation, Cytotherapy, vol.14, issue.10, pp.1258-1275, 2012.
DOI : 10.3109/14653249.2012.715243
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681879

E. Morris, K. Macdonald, and V. Rowe, NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs, Journal of Clinical Investigation, vol.115, issue.11, pp.3093-3103, 2005.
DOI : 10.1172/JCI25249DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253626

G. Renukaradhya, M. Khan, M. Vieira, W. Du, J. Gervay-hague et al., Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma, Blood, vol.111, issue.12, pp.5637-5645, 2008.
DOI : 10.1182/blood-2007-05-092866

P. Canchis, A. Bhan, S. Landau, L. Yang, S. Balk et al., Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d, Immunology, vol.80, issue.4, pp.561-565, 1993.

M. Dhodapkar, M. Geller, and D. Chang, A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma, The Journal of Experimental Medicine, vol.81, issue.12, pp.1667-1676, 2003.
DOI : 10.1182/blood.V97.7.2067

F. Fais, F. Morabito, and C. Stelitano, CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates ?-galactosylceramide presentation to natural killer T lymphocytes, International Journal of Cancer, vol.101, issue.3, pp.402-411, 2004.
DOI : 10.1002/ijc.11723

F. Fais, C. Tenca, and G. Cimino, CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis, Leukemia, vol.8, issue.4, pp.551-556, 2005.
DOI : 10.1182/blood-2003-04-1155

L. Metelitsa, K. Weinberg, P. Emanuel, and R. Seeger, Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells, Leukemia, vol.17, issue.6, pp.1068-1077, 2003.
DOI : 10.1038/sj.leu.2402943

C. Xu, R. De-vries, and L. Visser, Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma, American Journal of Hematology, vol.119, issue.7, pp.539-541, 2010.
DOI : 10.1002/ajh.21743
URL : https://hal.archives-ouvertes.fr/hal-00552329

C. De-lalla, A. Rinaldi, and D. Montagna, Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4- Subset Dynamics and Correlates with Remission State, The Journal of Immunology, vol.186, issue.7, pp.4490-4499, 2011.
DOI : 10.4049/jimmunol.1003748

D. Fulcher, D. Avery, and N. Fewings, Invariant natural killer (iNK)???T cell deficiency in patients with common variable immunodeficiency, Clinical & Experimental Immunology, vol.178, issue.2, pp.365-369, 2009.
DOI : 10.1111/j.1365-2249.2009.03973.x

N. Anandasabapathy, G. Breton, and A. Hurley, Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers, Bone Marrow Transplantation, vol.219, issue.7, pp.924-930, 2015.
DOI : 10.1038/bmt.2015.74